- Home
- WFG vs IONS Comparison
WFG vs IONS Comparison
Compare WFG & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFG
- IONS
- Stock Information
- Founded
- WFG 1955
- IONS 1989
- Country
- WFG Canada
- IONS United States
- Employees
- WFG N/A
- IONS N/A
- Industry
- WFG
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- WFG
- IONS Health Care
- Exchange
- WFG Nasdaq
- IONS Nasdaq
- Market Cap
- WFG 6.0B
- IONS 5.4B
- IPO Year
- WFG N/A
- IONS 1991
- Fundamental
- Price
- WFG $73.71
- IONS $33.51
- Analyst Decision
- WFG Buy
- IONS Buy
- Analyst Count
- WFG 3
- IONS 18
- Target Price
- WFG $105.00
- IONS $57.41
- AVG Volume (30 Days)
- WFG 143.0K
- IONS 1.5M
- Earning Date
- WFG 07-23-2025
- IONS 04-30-2025
- Dividend Yield
- WFG 1.74%
- IONS N/A
- EPS Growth
- WFG N/A
- IONS N/A
- EPS
- WFG N/A
- IONS N/A
- Revenue
- WFG $6,006,000,000.00
- IONS $717,253,000.00
- Revenue This Year
- WFG $1.36
- IONS $7.14
- Revenue Next Year
- WFG $8.10
- IONS $18.89
- P/E Ratio
- WFG $2,915.47
- IONS N/A
- Revenue Growth
- WFG N/A
- IONS N/A
- 52 Week Low
- WFG $69.48
- IONS $23.95
- 52 Week High
- WFG $102.40
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- WFG 47.30
- IONS 56.80
- Support Level
- WFG $72.66
- IONS $32.00
- Resistance Level
- WFG $74.97
- IONS $33.65
- Average True Range (ATR)
- WFG 1.55
- IONS 1.08
- MACD
- WFG -0.08
- IONS -0.10
- Stochastic Oscillator
- WFG 26.31
- IONS 55.72
About WFG West Fraser Timber Co. Ltd Common stock
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is now one of the largest oriented strand board producers in the world.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.